Table 1.
Baseline characteristics of the validation study sample (N = 437)
| Variables | Data |
|---|---|
| Sex, N (%) | |
| Women | 264 (60.5) |
| Age, mean years (SD) | 59.1 (11.8) |
| Educational level, N (%) | |
| No formal education | 92 (22) |
| Primary education | 181 (43.8) |
| Secondary education | 81 (19.4) |
| University or similar | 62 (14.8) |
| Carer status, N (%) | |
| Patient does not need care from other person | 292 (68.5) |
| Patient needs and receives care from the family, the caregiver, or both | 134 (31.5) |
| Time from diagnosis, mean years (SD) | 2.21 (3.9) |
| Karnofsky score on inclusion, mean (SD) [min, max] | 81.3 (11.6) [50, 100] |
| Cancer location, N (%) | |
| Breast | 147 (33.6) |
| Lung | 65 (14.9) |
| Colon | 50 (11.4) |
| Rectum | 34 (7.8) |
| Ovary | 27 (6.2) |
| Prostate | 22 (5) |
| Othera | 96 (22) |
| Cancer extension, N (%) | |
| Local | 90 (20.8) |
| Loco regional | 106 (24.5) |
| Metastasis | 237 (54.7) |
| Hb <11 g/dL, N (%) | 127 (29.1) |
| Hb (g/dL), mean (SD) [min, max] | 12 (1.7) [6.9, 18] |
| Treatment status, N (%) | |
| Follow-up surveillance | 43 (9.8) |
| Active treatment | 394 (90.2) |
| Type of cancer treatmentb, N (%) | |
| Chemotherapy | 368 (84.2) |
| Radiotherapy | 60 (13.7) |
| Hormone therapy | 48 (11) |
| Monoclonal antibodies | 41 (9.4) |
| Interferon | 6 (1.4) |
| VAS fatigue score on inclusion, mm; mean (SD) [min, max]**, c | 54.3 (15.1) [30, 95] |
| VAS fatigue level on inclusion, N (%) | |
| Moderate (30–60 mm) | 227 (65.6) |
| Severe (>60 mm) | 119 (34.4) |
| Following a fatigue treatment, N (%) | 152 (34.8) |
| FACT-Fd, mean (SD) | 35.9 (10.5) |
| NHP-22e, mean (SD) | |
| Physical summary score | 33.4 (24.1) |
| Psychological summary score | 34.2 (26.8) |
SD standard deviation, min minimum, max maximum, Hb haemoglobin, VAS visual analogue scale, NHP Nottingham Health Profile, FACT-F Functional Assessment of Cancer Therapy—Fatigue
aIncludes bladder (N = 18), pancreas (N = 16), lymphoma (N = 12), head and neck (N = 11), stomach (N = 10), and several other cancers with N < 5
bIncludes indiscriminately indications in single therapy and combined therapy
cFatigue was measured on a 100-mm, horizontal VAS
dGlobal score ranges from 13 (no impairment) to 65 (greatest impairment)
eDimension scores range from 0 (minimum impact in HRQOL) to 100 (maximum impact in HRQOL)